The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Field
Stäubli Technical Days 2025
We will be attending the Stäubli Technical Days 2025! Rochexpo – La Roche-sur-Foron (74) 8–11 December 2025 We invite you to come and discover the 7th edition of the Stäubli Technical Days, a highlight event focusing on robotics, automation and industrial innovation....
Industry Week 2025
At MGA, we are building the future together! For two weeks, our company had the pleasure of opening its doors to the younger generation and those involved in education. Middle school pupils, high school pupils, teachers: many of you came to discover our professions,...